QIAGEN N.V. provided preliminary unaudited earnings guidance for the fourth quarter and full-year 2015 and provided an outlook for 2016. For the full-year 2015, adjusted net sales are estimated to have risen approximately 3% at constant exchange rates (CER) compared to 2014, but to have declined about 5% at actual rates to approximately $1,280 million due to about eight percentage points of adverse currency movements of the U.S. dollar, Excluding the impact of lower U.S. sales of Human Papilloma Virus test products (cervical cancer screening), which created approximately three percentage points of headwind, adjusted net sales are estimated to have risen about 6% CER compared to 2014. Adjusted diluted earnings per share (EPS) are expected to have been approximately $1.13 to $1.14 CER for the full year compared to $1.00 in 2014. Adjusted diluted EPS results at actual rates are expected to have been approximately $1.05 to $1.06 and reflecting the impact of adverse currency movements.

For the fourth quarter of 2015, adjusted net sales are estimated to have risen approximately 3% at constant exchange rates (CER) compared to the fourth quarter of 2014, but to have declined approximately 3% at actual rates to approximately $348 million due to about six percentage points of adverse currency movements. About two percentage points of total CER growth are estimated to have come from the acquisitions of the Enzymatics NGS portfolio (acquired in December 2014), while sales from the rest of the business are expected to have provided about one percentage point compared to the fourth quarter of 2014. Adjusted net sales are estimated to have risen approximately 4% CER compared to the year-ago period. Adjusted diluted earnings per share (EPS) are expected to have been approximately $0.33 to $0.34 CER compared to $0.25 in the fourth quarter of 2014. Adjusted diluted EPS results at actual rates are expected to have been approximately $0.31 to $0.32 and reflect the impact of adverse currency movements.

The company provided its outlook for the full-year 2016, with expectations for adjusted net sales to rise approximately 6% CER from the current portfolio (including anticipated incremental contributions of less than one percentage point from 2015 acquisitions). These expectations do not take into account any further acquisitions that could be completed in 2016. Adjusted diluted earnings per share (EPS) for the full-year 2016 at CER are expected to rise approximately in line with sales. Based on exchange rates as of January 8, 2016, the company currently expects currency movements against the U.S. dollar to have an adverse impact of approximately two percentage points for the full-year 2016 on results for adjusted net sales and adjusted diluted EPS at actual rates.